Slide 1: First Quarter 2025 Earnings
First Quarter 2025 Earnings April 28, 2025
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: Key Takeaways
Key Takeaways Innovation Transformation Performance Expanded NGS partnership Solid organic growth driven by with Genomics England Leveraging strong execution Diagnostics & Software and balanced portfolio to Received FDA approval for appropriately navigate dynamic Strong synergy realization more auto
Slide 4: 1Q25 Revenue Highlights
1Q25 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU Recurring Non-recurring -LDD +LSD +MSD $0.7 B +LSD +MSD $0.7 B +MSD $0.7 B +MSD Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our w
Slide 5: 1Q25 Financial Results
1Q25 Financial Results REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $665M 25.6% $1.01 $118M +2% y/y +5bps y/y +4% y/y Organic: Adj. Gross Margin: Adj. Tax Rate: YTD FCF % Adj. NI: +4% | M&A: 0% | FX: -1% 61.7% | +80bps y/y 19.5% 97% Adj. Net Interest & Other: $18M Reconciliations to the mo
Slide 6: Life Sciences
Life Sciences LIFE SCIENCE SOLUTIONS SOFTWARE REVENUE AJUSTED OP MARGINS +DD 2% Organic Growth 31.1% Reported: 1% | M&A: 0% | FX: -1% +110bps y/y $340 M • +LSD growth from Pharma/Biotech, -LSD decline from 1Q25 revenue Academic/Gov’t -LSD • -LSD decline in Life Science Solutions; instrument declines
Slide 7: Diagnostics
Diagnostics IMMUNODIAGNOSTICS REPRODUCTIVE REVENUE AJUSTED OP MARGINS HEALTH 5% Organic Growth 22.8% Reported: 3% | M&A: 0% | FX: -2% -150 bps y/y +LSD $324 M • +HSD ImmunoDX globally; +LSD in China +HSD 1Q25 revenue • +LSD Reproductive Health globally driven by strength in newborn • Margin decline
Slide 8: 2025 Financial Guidance
2025 Financial Guidance REVENUE $2.83B - $2.87B Reported: 3% to 4% Organic: 3% to 5% FX: -0.5%, M&A: 0% ADJUSTED OP. MARGIN 27.9-28.1% ADJUSTED EPS $4.90 - $5.00 Adj. Net interest expense, other: ~$75M Adjusted tax rate: ~19% Average diluted share count: 119M 8
Slide 9: Revvity.com
Revvity.com